CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious ...
NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, ...
HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a collaboration with UCB to provide a broad range of in vitro pharmacology ...
A CNS-focused biopharmaceutical company headquartered in New York City. The company commercializes products in the United ...
SAGE Teams with CNS Expert Steven Paul, M.D.; Secures $35 million Series A to Accelerate Treatments for CNS Conditions; Expects to Launch First of Several Clinical Programs in 2012 Boston, Mass. - ...
News Medical on MSN
Considerations for taking ASO discovery programs into animal models
insights from industrySusanne BackAssociate Director of Central Nervous System (CNS) PharmacologyCharles River Laboratories ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, ...
A Holistic Arms Control Analysis (published by the Royal Society of Chemistry), co-authored by Dr Michael Crowley and ...
In this interview, Dr. Susanne Back explains the growing role of antisense oligonucleotides (ASOs) in neuroscience drug discovery. She discusses their benefits, challenges in administration, in vivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback